Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 01/07/2019
Entire Document
 

 

52 *Data from 20 patients Note: PBMC = Peripheral Blood Mononuclear Cell; Source: Tam et al. ASH 2016 (abstracts 642 and 1216) Zanubrutinib Achieves Complete and Sustained BTK Occupancy in Blood and Lymph Nodes PBMC* Lymph Node ▪ Complete BTK inhibition in PBMCs at the starting dose (40 mg) ▪ Paired lymph node biopsies were collected during screening or pre - dose on day 3 ▪ Median trough occupancy: 100% (160 mg BID) vs. 94% (320 mg QD ), p=0.002 ▪ Proportion ≥90% trough occupancy: 94% (160 mg BID) vs. 58% (320 mg QD ), p=0.027

 


© 2016 BeiGene. All Rights Reserved.